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Chikungunya virus (CHIKV) is an emerging viral pathogen that
causes both acute and chronic debilitating arthritis. Here, we
describe the functional and structural basis as to how two anti-
CHIKV monoclonal antibodies, CHK-124 and CHK-263, potently in-
hibit CHIKV infection in vitro and in vivo. Our in vitro studies show
that CHK-124 and CHK-263 block CHIKV at multiple stages of viral
infection. CHK-124 aggregates virus particles and blocks attach-
ment. Also, due to antibody-induced virus aggregation, fusion with
endosomes and egress are inhibited. CHK-263 neutralizes CHIKV in-
fection mainly by blocking virus attachment and fusion. To deter-
mine the structural basis of neutralization, we generated cryogenic
electronmicroscopy reconstructions of Fab:CHIKV complexes at 4- to
5-Å resolution. CHK-124 binds to the E2 domain B and overlaps with
the Mxra8 receptor-binding site. CHK-263 blocks fusion by binding
an epitope that spans across E1 and E2 and locks the heterodimer
together, likely preventing structural rearrangements required for
fusion. These results provide structural insight as to how neutraliz-
ing antibody engagement of CHIKV inhibits different stages of the
viral life cycle, which could inform vaccine and therapeutic design.
antibody | chikungunya virus | cryo-EM | epitope
Chikungunya virus (CHIKV), a single-stranded positive-senseRNA envelope virus, is an emerging alphavirus transmitted
to humans by Aedes species mosquitoes (1, 2). CHIKV consists
of three related genotypes: Asian, East/Central/South African
(ECSA), and West African (3). According to the Centers for
Disease Control and Prevention, there have been millions of
cases reported in approximately 100 countries. CHIKV infection
causes an acute febrile illness accompanied by musculoskeletal
disease (4, 5). A subset of cases (∼30%) showed that chronic
arthritis can develop and persist for months to years (6, 7).
The 12-kb positive-sense RNA genome is packaged within an
icosahedral nuclear capsid core composed of 240 copies of
capsid proteins, which is surrounded by a host-derived lipid bi-
layer. The surface of the mature CHIKV particle (diameter ∼700
Å) has 80 trimeric envelope E1-E2 heterodimer protein spikes
anchored on the lipid bilayer membrane (SI Appendix, Fig. S1A)
arranged in T = 4 icosahedral symmetry. E1 and E2 protein
ectodomains each consist of three domains: E1-DI; E1-DII and
E1-DIII; and E2-DA, E2-DB, and E2-DC (SI Appendix, Fig.
S1B). The fusion loop on the distal end of E1-DII mediates
endosomal membrane fusion. The groove formed by E2-DA and
E2-DB shields the fusion loop of E1 protein from premature
membrane fusion at neutral pH (8). Multiple attachment factors
have been implicated in CHIKV entry of cells (9), and E2-DB
reportedly contains receptor-binding sites (10, 11). Mxra8, a recently
identified alphavirus receptor (12), recognizes an epitope spanning
both the E1 and E2 proteins (13, 14).
The virus infection cycle starts with the E1-E2 proteins binding
to the cell-surface receptors (12). The virion is then internalized
into the endosome (15, 16). The acidic condition of the endosome
causes E1-E2 heterodimers to undergo conformational changes,
exposure of the E1 fusion loop for insertion into the endosomal
membrane, and subsequent reorganization of the E1 protein into
E1 trimers to allow endosomal membrane fusion (17, 18). After
fusion, the capsid and RNA genome are released into the cytoplasm
(19) to allow translation and replication of the viral genome. The
newly synthesized virus buds at the plasma membrane (20).
Currently, there exist no licensed CHIKV vaccine or therapeutics.
Neutralizing antibodies have been shown to confer both prophy-
lactic and therapeutic protection in animal models (21–28). Here
we show the potencies of two CHIKV antibodies, CHK-124 and
CHK-263, in vivo and demonstrate that they inhibit multiple steps
in the virus infection cycle in vitro. We also determined the
cryogenic electron microscopy (cryo-EM) structures of their Fab
fragments complexed with CHIKV to 4- to 5-Å resolution. For
CHK-124, the predominant neutralization mechanisms are ag-
gregation of virus particles and inhibition of receptor binding. For
CHK-263, the mechanism is the inhibition of fusion by locking E1
and E2 proteins together. Altogether, our study provides a struc-
tural understanding as to how potent antibodies block CHIKV
infection.
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portant information that will advance antibody therapeutics
and vaccine development against this emerging pathogen.
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CHK-124 and CHK-263 Are Potently Neutralizing In Vivo. We previ-
ously reported that the mouse monoclonal antibodies (mAbs)
CHK-124 and CHK-263 exhibit potent neutralizing activity in vitro
using focus reduction neutralization tests (21). We confirmed the
neutralization activity of CHK-124 and CHK-263 using a separate
assay (a plaque reduction neutralization test [PRNT]50 of 1.8 and
3.8 ng/mL) against a clinical isolate CHIKV East African strain in
Vero cells using PRNT (SI Appendix, Fig. S2).
We next evaluated the efficacy of CHK-124 and CHK-263
in vivo using a wild-type (WT) C57BL/6 mouse model of CHIKV
arthritis and musculoskeletal disease by subcutaneous inocula-
tion in the foot (29, 30). Treatment with CHK-124 or CHK-263
prior to CHIKV inoculation significantly reduced foot swelling at
3 d post infection (3 dpi) (Fig. 1A). This phenotype was associ-
ated with reduced levels of viral RNA in the ipsilateral ankle
(Fig. 1B), diminished viremia, reduced infection of the spleen,
and decreased spread to contralateral ankle and gastrocnemius
(calf) muscle compared to the isotype control mAb (Fig. 1 C–E).
Thus, CHK-124 and CHK-263 are potently neutralizing mAbs
in vitro and confer protective activity in vivo.
To investigate whether the inhibitory activity of these anti-
bodies requires FcR effector functions, we repeated the same
infection experiments in congenic mice lacking the Fc receptor
common gamma chain (FcRγ−/−). In WT mice, both antibodies
prevented CHIKV-induced infection and joint swelling, with
CHK-124 showing slightly better prevention activity than CHK-263.
However, this pattern was reversed in FcRγ−/− mice (Fig. 1 F–J).
Thus, the in vivo inhibitory activity of CHK-124 is partially FcRγ-
dependent whereas the protective effect of CHK-263 is largely
independent.
CHK-124 and CHK-263 Block Multiple Pathways in the Virus Infection
Cycle. Antibodies can neutralize virus infection by different
mechanisms including aggregation of virus particles, prevention
of viral attachment, fusion inhibition, or viral egress blockade.
To investigate whether CHK-124 and CHK-263 inhibit viral
entry, we conducted preattachment and postattachment neutrali-
zation assays (21, 31). In these assays, antibody was added either
before or after the virus attachment to cells, respectively. The
preattachment neutralization assay determines if antibodies block
viral engagement prior to cellular attachment (e.g., through ag-
gregation of virions or inhibition of attachment to cells). Both
CHK-124 IgG and CHK-263 IgG neutralize primarily by inhibiting
preattachment stages of infection with the PRNT50 value of 3.2
and 5.5 ng/mL, respectively (Fig. 2A), whereas their PRNT50
values are poorer in postattachment neutralization—21.2 and
10.8 ng/mL, respectively. In the postneutralization assay, both
CHK-124 IgG and CHK-263 IgG were unable to neutralize 30%
of virus even at high antibody concentrations. This phenotype
also was observed previously for other antibodies (21, 32, 33).
Fig. 1. CHK-124 and CHK-263 protect mice against CHIKV diseases and dissemination. (A–J) CHK-124 and CHK-263 mAbs reduced foot swelling and the viral
RNA levels in ankles, muscles, blood, and spleen of CHIKV-infected wild-type (A–E) or congenic FcRγ−/− (F–J) mice. Four-week-old wild-type or FcRγ−/− C57BL/6
mice were treated with 100 μg of CHK-124, CHK-263, or an isotype control (WNV E60) 1 d before infection with 103 FFU of CHIKV. (A and F) Foot swelling was
measured at 3 dpi. Horizontal line indicates mean values (n = 5 to 10/group; two experiments; one-way ANOVA with a Tukey’s posttest; ****P < 0.0001). (B
and G) Ipsilateral ankle, (C and H) serum, (D and I) spleen, and (E and J) contralateral ankle and gastrocnemius (calf) muscle were harvested 3 dpi, and viral
RNA levels were determined by qRT-PCR. Bars indicate median values (n = 5 to 10/group); two experiments; Kruskal–Wallis with a Dunn’s posttest; *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001). Each symbol in this figure represents data from an individual mouse.



















































Although the reason is not known, we speculate that, when the
virus is first allowed to bind to the cell surface, some particles
engaging the cell are less accessible to antibody binding. Be-
cause these regions cannot be bound by antibody, the stoichi-
ometry of binding required for virus neutralization may not be
achieved (33) and these viral particles still can carry out entry
and fusion.
We also conducted preattachment and postattachment neu-
tralization assays with Fab fragments of CHK-124 and CHK-263;
they are consistently less neutralizing than their IgG counter-
parts (Fig. 2A). In the preattachment neutralization, CHK-124
Fab (PRNT50 = 152.9 ng/mL) and CHK-263 Fab (PRNT50 =
13.9 ng/mL) have 47- and 2.5-fold poorer activities than the
corresponding IgG. In the postattachment neutralization assay,
CHK-124 Fab completely lost its neutralization activity, whereas
CHK-263 Fab has 1,000-fold less activity (PRNT50 = ∼10 μg/mL)
than its IgG. Thus, bivalent binding and/or virus cross-linking
likely enhances the ability of these antibodies to neutralize vi-
rus. This is especially important for CHK-124.
To determine if the antibodies aggregate virions in solution,
we added different molar ratios of IgG to virion and measured
their hydrodynamic size using dynamic light scattering (Fig. 2B).
CHK-124 started aggregating virus particles at IgG:virus molar
ratios above 25:1, which correlated with its neutralizing activity.
In comparison, CHK-263 did not aggregate virus at any IgG:virus
molar ratios tested, including molar ratios above 25:1. The cryo-
EM images of these complexes at a IgG:E2 (on virus) molar ratio
of 1.5:1 also showed CHK-124 IgG severely aggregated viruses
whereas CHK-263 did not (SI Appendix, Fig. S3).
We next tested whether CHK-124 and CHK-263 could inhibit
CHIKV binding to cells. We preincubated CHIKV with IgG or
their Fabs at neutralizing concentrations prior to adding to Vero
cells at 4 °C, which prevents virus internalization. The amount of
cell-bound virus was then determined by RT-qPCR. Both CHK-
124 IgG and CHK-263 IgG at the concentrations tested (0.1 to
10 μg/mL) inhibited virus attachment to cells (Fig. 2 C, Left).
Their Fab fragments retained their ability to inhibit virus at-
tachment to cells, although less efficiently (Fig. 2 C, Right). This
indicates that bivalency of IgG enhances the inhibitory effect on
virus attachment.
Upon viral entry, antibodies can inhibit endosomal membrane
fusion and penetration into the cytoplasm. To determine if
CHK-124 and CHK-263 inhibited fusion, we used an in vitro
system, where 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbo-
cyanine, 4-chlorobenzenesulfonate salt (DiD)-labeled purified
CHIKV particles were tested for their ability to fuse with lipo-
somes in the presence or absence of antibodies. In cases where
fusion occurs, the DiD in the viral membrane is diluted within
Fig. 2. CHK-124 and CHK-263 target multiple pathways in the CHIKV in-
fection cycle. In general, CHK-124 inhibitory activities were more dramati-
cally reduced when bivalency of IgG was abolished by the use of Fab
fragments compared to CHK-263. (A) CHK-124 and CHK-263 IgGs are highly
neutralizing in both pre- and postattachment neutralization assays, whereas
their Fabs have weaker activities. PRNT50 values indicating the antibody
concentration that neutralized 50% of the plaque-forming units was de-
termined by curve fitting using nonlinear regression in GraphPad Prism v8.0.
(B) CHK-124 IgG induced virus aggregation, which correlates with its neu-
tralization profile, whereas CHK-263 does not cause virus aggregation. The
hydrodynamic size of CHIKV:CHK-124 IgG and CHIKV:CHK-263 IgG com-
plexes in a different IgG:virion molar ratio was measured by dynamic light
scattering (black curve). The neutralization profile of these CHIKV:IgG
complexes (red curve) is shown as a neutralization index (right y axis) cal-
culated as the log10 fold reduction of the virus titer compared to the virus-
only control. (C) Both CHK-124 and CHK-263 IgG and Fab prevent virus from
attaching to cells if antibody:CHIKV complex is formed before addition to
cells. Isotype IgG/Fab and no antibody controls were included. (D) Virus:lipo-
somal membrane fusion assays showed that both IgGs of CHK-124 and CHK-
263 inhibit virus:liposomal membrane fusion at pH 5.5, similar to the positive
control (dethylpyrocarbonate [DEPC]). When Fab fragments were used, the
inhibitory effect of CHK-124 was abolished whereas that of CHK-263 Fab was
maintained. The extent of fusion was calculated as the percentage of the
fluorescence emission before adding Triton X-100 to the full fluorescence
emission after adding Triton X-100. (E) CHK-124 has stronger inhibitory ac-
tivity of viral egress than CHK-263. (A–E) Data are the mean ± SEM from at
least three independent experiments. Significance was determined by one-
way ANOVA with Dunnett’s posttest compared to isotype control. (**P <
0.01, ***P < 0.001, ****P < 0.0001).



























































the liposomal membrane, thereby emitting fluorescence. Both
CHK-124 and CHK-263 IgG inhibited membrane fusion in a
dose-dependent manner (Fig. 2 D, Left). However, CHK-124
Fab was unable to inhibit fusion (Fig. 2 D, Right), possibly due to
its inability to aggregate virions in a monovalent form (Fig. 2B).
In comparison, CHK-263 Fab moderately inhibited virus fusion
with liposomes (Fig. 2 D, Right).
We next evaluated whether both IgG and Fab of CHK-124
and CHK-263 block virus egress. We inoculated cells with CHIKV
and then removed unbound virus particles 1 h later through ex-
tensive rinsing of monolayers. Subsequently, mAbs were added
and, 1 h later, viral RNA was measured in the supernatant; as
expected, at this early time point, no antibody inhibitory effect was
detected (SI Appendix, Fig. S4). We then measured the amount of
viral RNA at 6 h post infection, when the first round of virus se-
cretion started. Compared to the no mAb or isotype control mAb
conditions, CHK-124 IgG has a greater ability to inhibit viral
egress than CHK-263 IgG (Fig. 2 E, Left). The Fab fragments of
CHK-124 and CHK-263 has less and virtually no ability to block
egress, respectively (Fig. 2 E, Right).
The cryo-EM Structures of CHIKV Complexed with Fab Fragments of
CHK-124 and CHK-263. To determine CHK-124 and CHK-263
epitopes, we performed cryo-EM studies using Fab fragments of
these antibodies complexed with CHIKV. Micrographs showed
that preincubation with CHK-124 or CHK-263 Fab fragments
Fig. 3. The cryo-EM maps of CHIKV complexed with Fab fragment of CHK-124 or CHK-263. (A and B) The cryo-EM density maps of CHIKV:CHK-124 Fab (A)
and CHIKV:CHK-263 Fab (B) were determined to 5.2- and 4.7-Å resolutions, respectively. Their surface and a cross-section of a quarter of cryo-EM density maps
are shown in the Left and Right panels, respectively. The black triangles represent an icosahedral asymmetric unit, and their five-, three-, and two-fold vertices
are indicated. The E1-E2 heterodimers in one icosahedral asymmetric unit are colored as blue. (C and D) Top (Left) and side (Right) view of the binding of CHK-
124 Fab (C) and CHK-263 Fab (D) to an asymmetric unit of CHIKV surface E1-E2 proteins. CHK-124 Fabs bind to all individual E1-E2 heterodimers within an
asymmetric unit in an orientation perpendicular to the virus lipid envelope surface. CHK-263 Fabs lie laterally to the virus surface binding to three of the four
E1-E2 (molecules A–C but not D). The Fab A (dashed circle) density is poor, suggesting partial occupancy around the five-fold vertex. E1:E2 heterodimers are
shown as ribbons and the Fab molecules as surface representations. CHK-124 and CHK-263 Fab molecules are colored in gray and pink, respectively. The CHIKV
E1, E2, and capsid proteins are colored in yellow, green and red, respectively. Vertices are indicated. (E) Localized reconstruction of subregions around the
five-fold vertices in the CHIKV:CHK-263 Fab-complexed structure (cyan circle in B, Left). Results showed five different classes of the subparticles. All indicate
that at most only two Fabs can bind around the five-fold vertex and are unable to bind to two E1-E2 heterodimers located right next to each other. The Fab
densities are colored as hot pink, and the E1-E2 heterodimers bound by these Fabs are colored in dark green. (Right) The averaged map of these classes after
they have been rotationally aligned to each other at 4.5-Å resolution.



















































did not aggregate virus or substantially alter its morphology (SI
Appendix, Fig. S5).
The cryo-EM reconstructions of CHIKV:CHK-124 Fab and
CHIKV:CHK-263 Fab were determined to 5.2- and 4.7-Å reso-
lutions, respectively, based on the Fourier Shell Correlation
cutoff of 0.143 (SI Appendix, Figs. S6A and S7A). Binding of
CHK-124 Fab and CHK-263 Fab to CHIKV did not induce large
conformational changes to the overall quaternary virus structure,
with the root mean square deviation (rmsd) values of 1.497 and
1.596, respectively, compared to unliganded CHIKV-VLPs (Pro-
tein Data Bank [PDB] ID: 6NK5) (13). We observed 240 CHK-
124 Fab fragments bound to the CHIKV virion at the top of the
spikes, orienting perpendicularly with respect to the viral lipid
envelope (Fig. 3A and SI Appendix, Fig. S6 A–C).
CHK-263 Fab fragments, in contrast, bound laterally to the
E1-E2 heterodimers on the virus surface (Fig. 3B). We observed
Fab densities at the two- and five-fold vertices but not in the E1-E2
trimeric spikes at the three-fold vertex. Although the Fab densities
were observed around the five-fold vertex, weaker electron density
likely indicates partial occupancy (Fig. 3B). To understand how
CHK-263 Fab binds around the five-fold vertex, we performed lo-
calized three-dimensional (3D) reconstruction (34) with classifica-
tion but no shift or rotation alignment nor symmetry averaging
imposed. The result shows five classes of subparticles (Fig. 3E), with
different combinations of two Fab molecules binding to two dif-
ferent E1-E2 heterodimers. Consistent among these classes, we
observed that the two Fab molecules around the five-fold vertex
were unable to bind to their immediate neighboring E1-E2 heter-
odimers, likely due to the need for spacing to avoid steric hindrance
between Fabs. To obtain a higher resolution map, we combined the
subregion classes by rotational alignment and then averaged them
(35). The structure of the averaged subregions showing two Fabs
bound around the five-fold vertex was determined to a resolution of
4.5-Å (Fig. 3E and SI Appendix, Fig. S7B). We also performed lo-
calized reconstruction for subregions around the three-fold vertex
and two-fold (also known as quasi-six-fold) vertex (SI Appendix,
Fig. S7 C and D). Their structures are similar to the icosahedrally
averaged CHKV:CHK-263 complex. No Fabs were bound near
the three-fold vertex. Around the icosahedral two-fold (or
quasi-six-fold) vertex, the occupancy of CHK-263 Fab is not full:
only four of the six epitopes are bound (SI Appendix, Fig. S7D).
The occupancy here is greater than around the five-fold vertex,
which has only two Fabs bound, because there is more space and
less steric hindrance around the quasi-six-fold vertex. Overall,
CHK-263 Fab showed selective binding to the E1-E2 proteins on
the virus surface with only 144 Fabs (60% occupancy) bound to
the virion.
We then interpreted the cryo-EM density by fitting the CHK-
124 and CHK-263 Fabs and the CHIKV E1-E2 heterodimer into
their corresponding densities (SI Appendix, Figs. S6D, S7E, and
Table S1). Contrary to the previously determined CHIKV-181/
25 cryo-EM structure (13, 32), we did not observe densities
corresponding to the E3 protein, a protein present on immature
CHIKV. Fitting of the complexed particles and subregions at
different vertices showed similar Fab:epitope-interacting inter-
faces. Due to the resolution, some side-chain densities cannot be
placed accurately. We thus identified the likely contact residues
between the CHIKV envelope proteins and the Fab molecules
using a cutoff of distance <∼8 Å between pairs of Cα atoms. We
also considered the local hydrophilic or hydrophobic environment.
Within an asymmetric unit, all four CHK-124 Fab molecules
bind to E2 proteins in a similar conformation (Fig. 3C) with an
average rmsd value of 0.813 (SI Appendix, Fig. S8A). The binding
interfaces of the CHK-124 Fab molecules on the E2 protein
occlude ∼489 Å2 of surface area. The interaction is focused on a
small region on the outer surface of the E2-DB, without con-
tacting the E1 protein or adjacent E1-E2 heterodimers (Fig. 3C).
CHK-124 Fab primarily binds to two peptides on the E2-DB
(Fig. 4A). One peptide fragment is located in the ABBB loop and
extends to the BB strand (Fig. 4A and SI Appendix, Fig. S9A). A
second peptide fragment stretches from the EB strand to the
EBη3 loop. The paratope of the CHK-124 Fab consists of resi-
dues from the heavy chain and light chain (Fig. 4 B, Top, and SI
Appendix, Table S2). The epitope and paratope side-chain charges
are not highly complementary (Fig. 4 B, Top), suggesting that
some side chains may interact with the main chain, similar to that
found in other virus-antibody studies [e.g., the Zika virus-C8 mAb
interaction (36)].
Despite the different chemical environments, the three bound
CHK-263 Fabs (A, B, and C) interact with the CHIKV E1-E2
heterodimer in a similar conformation (Fig. 3D) with average
rmsd values of 0.896 (SI Appendix, Fig. S8B). In contrast to CHK-124,
the CHK-263 Fab molecule has a larger footprint (∼918 Å2). The
epitope on the CHIKV envelope proteins spans across E1 and
E2 proteins (Fig. 4A), and it has complementary charges to the
paratope (Fig. 4 B, Bottom, and SI Appendix, Table S3).
Most of the residues in the epitope of CHK-263 are located in
the E2-DB, engaging the CB strand, CBC′B loop, C′B strand,
C’BEB loop, and the EB strand (Fig. 4A and SI Appendix, Fig.
S9A). The β-linker connecting E2-DB with E2-DC and two
residues (K61 and C63) on the E1-DII also contribute to the
interaction with the CHK-263 Fab molecule.
In conclusion, the cryo-EM structures of CHIKV complexed
with the Fab fragments of CHK-124 and CHK-263 showed that
the CHK-124 Fab binds exclusively to E2-DB, whereas CHK-263
Fab binds to an epitope spanning E2-DB, E2 β-linker, and E1-
DII. We subsequently used biolayer interferometry to determine
the affinity of the CHK-124 and CHK-263 Fabs to CHIKV.
Notably, CHK-263 Fab binds to CHIKV with a KD of ∼2.5 nM,
which is an ∼20-fold higher affinity than the CHK-124 Fab (45.4
nM) (SI Appendix, Fig. S10). This higher affinity of binding corre-
lates with the footprint area of Fabs on CHIKV, as CHK-263 has a
two-fold larger interface (∼918 Å2) than CHK-124 (∼489 Å2).
Cryo-EM Structure of CHK-263 IgG Complexed with CHIKV. Since
CHK-263 IgG does not aggregate CHIKV, we determined the
icosahedrally averaged structure of the CHIKV:CHK-263 IgG
complex to 5.9-Å resolution (Fig. 5A and SI Appendix, Fig.
S11A). The location of the densities of the CHK-263 IgG
(Fig. 5A) largely overlap with the Fab:CHIKV complex (Fig. 3B
and SI Appendix, Fig. S11B). In addition, there are some addi-
tional weak densities above the Fab that likely belong to the Fc
region of the IgG around both five- and two- (or quasi-six-) fold
vertices (SI Appendix, Fig. S11A). The poor densities of the Fc
could be due to icosahedral averaging, so we conducted localized
reconstruction of the regions around the five- and two- (or
quasi-six-) fold vertices without imposing symmetry. The IgG den-
sities around the five-fold vertex did not improve: the Fab and Fc
region densities were weak, likely because the IgG binding is flexible.
As for the two-fold (quasi-six-fold) vertex, asymmetric localized
reconstruction yielded a 9.4-Å resolution map (SI Appendix, Fig.
S11C), clearly showing two hinge densities (Fig. 5 B and C and SI
Appendix, Fig. S11C) (hinge region links the Fabs to the Fc re-
gion of IgG). This suggests that, around this vertex, two IgG
molecules can bind at the same time (Fig. 5 B and C). Although
we were unable to determine specifically which two Fab mole-
cules belongs to an IgG, we narrowed down the binding mode of
the IgGs to two possibilities (Fig. 5D) by measuring distances
between neighboring Fabs (distance between two Fabs in an IgG
should be <87 Å [PDB ID: 1IGT]) (37).
Discussion
A previous study (21) and our current study demonstrate that
mAb CHK-124 and CHK-263 are highly neutralizing in vitro
across strains from the three CHIKV genotypes (ECSA, Asian,
and West African) as well as other alphaviruses. Sequence



























































comparison shows that the CHK-124 epitope on E2-DB is con-
served across not only the three CHIKV genotypes but also across
other alphaviruses including O’nyong’nyong virus (ONNV),
Mayaro virus (MAYV), Ross River virus (RRV), Sagiyama virus,
Semliki Forest virus (SFV) and Una virus (SI Appendix, Fig. S9B).
This is consistent with the previous study showing that CHK-124
broadly neutralizes CHIKV, MAYV, SFV, and ONNV (26). The
CHK-263 epitope across E1 and E2 also showed high conserva-
tion across the three CHIKV genotypes (SI Appendix, Fig. S9A),
consistent with its cross-neutralization activities.
Most anti-CHIKV antibodies (e.g., 5F10, CHK-265, and RRV-12)
that have been characterized structurally (26, 32, 38–40) are
similar to CHK-124, as they bind largely to E2-DB. CHK-263 and
CHK-166 (21) are interesting as they both bind across E1 and E2
Fig. 4. Epitopes bound by CHK-124 Fab and CHK-263 Fab. (A) Binding mode of CHK-124 Fab (Top) and CHK-263 Fab (Bottom) to the ectodomains of an E1-E2
heterodimer. Epitopes of CHK-124 and CHK-263 are shown as blue and pink spheres, respectively, on an E1-E2 heterodimer (Middle and Right). (Right) Zoom-
in view of the epitope with strands labeled. (B) Open book representation showing the electrostatic potential of the interacting interface between the
epitope and paratope of CHIKV:CHK-124 (Top) and CHIKV:CHK-263 Fab (Bottom) structures. Positive, negative, and neutral charged residues are colored in
blue, red, and white, respectively. Cyan dashed lines indicate the boundaries of the antibody heavy and light chains in the paratope and also its corresponding
binding epitope. Residues at the interacting interface are indicated.



















































proteins, although only the epitope of CHK-263 is confirmed struc-
turally. A possible reason for why most antibodies bind only to E2
could be due to its higher solvent accessibility compared to E1
protein, which is partially hidden underneath. We also showed
that CHK-263 Fab has a 20-fold higher affinity than CHK-124
Fab, which correlates to the size of their footprints.
In the structure of the CHIKV:CHK-263 Fab complex, only
three (E1-E2 molecules [mols] A to C) of the four epitopes were
engaged by the Fabs within an asymmetric unit even though all
epitopes are accessible (mols A to D) (Fig. 3D). Superposition of
CHK-263 Fab fragment onto E1-E2 mol D shows that this Fab
would clash with the neighboring bound Fabs B and C′ (from the
neighboring asymmetric unit) (SI Appendix, Fig. S12). Thus, binding
of Fabs to either E1-E2 mols B or C′ could block engagement of
Fab to E1-E2 mol D. This suggests that, at low antibody con-
centrations, if both E1-E2 mols B and C are not occupied, Fab
may be able to engage E1-E2 mol D.
Both CHK-124 and CHK-263 inhibit virus attachment to cells.
Mxra8 receptor had been shown to bind across different E1-E2
heterodimers on the CHIKV surface and its epitopes include E2-
DA and E2-DB; E2 β-linker; and E1-DII (13, 14). Superposition
of Mxra8 and CHK-124 Fab onto the E1-E2 heterodimer shows
clashes (Fig. 6A). This suggests that CHK-124 may inhibit CHIKV
from binding to the Mxra8 receptor. Indeed, our direct-binding
Fig. 5. The cryo-EM structure of CHIKV complexed with CHK-263 IgG. (A) Surface of the cryo-EM structure of CHIKV complexed with CHK-263 IgG. E1, E2, and
IgG are colored in green, yellow and magenta, respectively. (B) The cryo-EM map of the localized reconstruction of subregions around the two-fold (quasi-six-
fold) vertex of CHIKV:CHK-263 IgG complex, displayed at different contour levels. The densities corresponding to the Fabs of the IgG are colored in magenta,
while their bound E1-E2 heterodimers are colored in dark green. Blue densities indicate two hinge densities each from an IgG. We therefore detected two
IgGs bound around the two-fold vertex. (C) Zoom in side view of the bound IgGs. Black arrows pointing to the two hinges (in blue) each from an IgG. Weak
densities corresponding to the Fc regions are colored in gray. (D) Two possible arrangements of the two IgGs around the two-fold vertex. The densities of two
Fabs possibly from an IgG are in the same color. Distance between the adjacent Fab molecules of CHK-263 IgG is indicated in red fonts above the red lines.
Measurement of an IgG crystal structure (PDB ID: 1IGT) shows that the distance between two Fabs in an IgG is within 87 Å.
Fig. 6. Superposition of the CHIKV receptor Mxra8 onto the cryo-EM structures of the CHIKV:Fab complexes. (A and B) Superposition of the CHIKV receptor
Mxra8 to the CHK-124 Fab (A) and CHK-263 Fab (B) structures within an asymmetric unit (Left). Zoom-in side views of E1-E2 heterodimer (Right) show that the
binding of CHK-124 may clash with Mxra8, whereas CHK-263 Fab and Mxra8 can bind simultaneously to the E1-E2 heterodimer. E1: yellow ribbons; E2: green
ribbons; Mxra8: blue surfaces; CHK-124: gray surfaces; CHK-263: pink surfaces. (C) CHK-124 IgG can strongly inhibit virus from binding to Mxra8 whereas CHK-
263 IgG has only moderate activity. Blocking of Mxra8-Fc binding to CHK-124 or CHK-263 complexed CHIKV was determined by competition ELISA. CHIKV
VLPs were captured with CHK-152 and CHK-166 before addition of the CHIKV mAbs or Mxra8-mouse-Fc followed by Mxra8-hu-Fc (human Fc). Black circles
indicate Mxra8-hu-Fc binding to CHIKV VLP in the absence of anti-CHIKV mAbs. A rightward shift of the curve indicates competition of CHIKV mAbs with
Mxra8-mFc for binding to CHIKV. Data are the mean ± SEM from two independent experiments performed in duplicate.



























































enzyme-linked immunosorbent assay (ELISA) data showed that
CHK-124 IgG strongly blocked Mxra8 binding to CHIKV virions
(Fig. 6C). Antibody-induced virus aggregation had been shown to
reduce the number of infectious units (41), but it may not prevent
these aggregated viruses from attaching to cells (42, 43). For
CHK-124, we observed that, in addition to causing virus aggre-
gation (Fig. 2B and SI Appendix, Fig. S3), it also prevents viral
attachment to cells (Fig. 2 C, Left), likely because Fab specifically
blocks Mxra8 receptor binding. This idea is supported by the ob-
servation that, when aggregation is abolished using Fab fragments,
virus attachment to cells is still inhibited (Fig. 2 C, Right). As the
CHK-263 epitope does not overlap with the Mxra8-binding site
(Fig. 6B), its virus-attachment–inhibiting activity might target other
unknown attachment factors (9).
From the aggregation assay data (Fig. 2B) and cryo-EM im-
ages (SI Appendix, Fig. S3), we showed that CHK-263 does not
cause aggregation of virus. The asymmetric localized recon-
struction of the CHK-263 IgG complexed with CHIKV around
its two-fold (quasi-six-fold) vertex showed that there are two IgG
molecules bound (Fig. 5 B–D). Since the Fab arms of both IgGs
are engaged, they are unlikely to cross-link other virus particles,
thereby preventing virus aggregation. We were unable to deter-
mine the structure of the CHK-124 IgG complexed with CHIKV,
as this antibody aggregates virus particles (SI Appendix, Fig. S3).
To understand the mechanism of how this antibody causes ag-
gregation, we superimposed a Fab arm of the crystal structure of
an IgG (37) onto the Fabs in the cryo-EM structure of the
CHIKV:CHK-124 Fab complex (SI Appendix, Fig. S13A). This
shows that when one arm of the Fab of an IgG is bound to the
virus, another Fab points away to engage other virus particles (SI
Appendix, Fig. S13 A and B).
In conclusion, both CHK-124 and CHK-263 potently inhibit
different steps of the virus infection cycle. The major neutrali-
zation mechanism of CHK-124 IgG is antibody-induced aggre-
gation, which inhibit virus-endosomal membrane fusion and
egress. Aggregation of virions in solution or viral antigen on the
plasma membrane of cells may more efficiently activate effector
functions and immune cells (44, 45). This idea is consistent with
the greater dependency of CHK-124 on FcRγs for protection. A
more specific inhibitory mechanism of CHK-124 is that it directly
blocks virus interaction with the Mxra8 receptor. In contrast,
CHK-263 binds laterally to the virus surface and its epitope
spans across E1 and E2 proteins. While the mechanism by which
CHK-263 partially blocks virus attachment to cells requires fur-
ther investigation, its ability to bridge E1 and E2 together likely
prevents E1 dissociation from E2 during endosomal fusion. The
thorough understanding of the neutralization mechanisms and how
the antibodies interact with virus particles could inform the devel-
opment of vaccines and therapeutics to combat CHIKV infection.
Materials and Methods
A detailed description of all materials and methodology is included in SI
Appendix, Materials and Methods. This includes the cells and virus, mAb
CHK-263 and CHK-124 production and digestion, plaque reduction neu-
tralization test, in vivo experiments, pre- and postattachment neutralization
assays, dynamic light scattering assay, attachment RT-qPCR assay, DiD-labeled
virus fusion assay, virus egress assay, Mxra8-blocking experiment, biolayer
interferometry assay, statistical analysis, cryo-EM sample preparation, data
collection, processing, and analysis.
Sample Preparation for Cryo-EM. CHIKV virus samples were mixed with the
CHK-263 Fab or CHK-124 Fab or CHK-263 IgG at a molar ratio of 1.5 Fab/IgG
to every E2 protein, incubated at 37 °C for 30 min, and then kept at 4 °C
before freezing on cryo-EM grids. About 2 μL of the sample was applied to a
precooled cryo-EM grid with lacey carbon covered with a thin carbon film.
The grid was then blotted with filter paper at 4 °C with 100% humidity for 1
to 2 s and flash-frozen in liquid ethane by using the Vitrobot Mark IV
plunger (FEI).
Data Collection and Image Processing. The images of the frozen CHIKV-
Ross:CHK-124 Fab complex, CHIKV-East African:CHK-263 Fab complex, and
CHIKV-East African:CHK-263 IgG complex were taken with the FEI Titan Krios
electron microscope at 300 keV with a nominal magnification of 47,000×
and a FEI Falcon II direct electron detector. Images were collected using
Leginon (46) in movie mode, with a total exposure of 2 s and a total dose of
∼20 e−/Å2. The frames from each movie were aligned using MotionCorr (47)
to produce full-dose images used for particle selection and orientation
search, and the images from the first several frames amounting to the dose
of about 20 e−/Å2 were used in 3D reconstruction. The images were taken at
a defocus range of 0.5- to 2.5-μm. cisTEM (48) and Gctf (49) were used to
estimate the astigmatic defocus parameters. Particle picking was undertaken
using cisTEM. Orientation search and 3D reconstruction of the picked particles
were performed using cisTEM and RELION (50, 51). The reconstruction process
is detailed in SI Appendix, Materials and Methods and Table S1.
Data Availability. The cryo-EM map of the CHIKV:CHK-124 Fab complex,
CHIKV:CHK-263 Fab complex, CHIKV:CHK-263 IgG complex, subregion around
the five-fold vertex of the CHIKV:CHK-263 Fab complex, and subregion around
the two-fold vertex of the CHIKV:CHK-263 IgG complex has been deposited
in the Electron Microscopy Data Bank under the accession codes EMD-
30476, EMD-30477, EMD-30478, EMD-30479, and EMD-30480, respectively.
Their atomic models have been deposited in the Protein Data Bank under
the accession codes 7CVY, 7CVZ, 7CW0, 7CW2, and 7CW3, respectively.
All study data are included in the article and supporting information.
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